RPG Life Sciences Acquires Raghava Life Sciences' API Division for ₹135 Crore

Mumbai, India — RPG Life Sciences has announced a strategic acquisition of the Active Pharmaceutical Ingredients (API) business from Raghava Life Sciences, a move valued at ₹135 crore. This acquisition marks a significant milestone in RPG Life Sciences' expansion strategy and strengthens its position in the pharmaceutical sector.

The purchase will enable RPG Life Sciences to enhance its product portfolio and expand its reach in the API market, a sector critical to the pharmaceutical supply chain. The company plans to integrate Raghava’s API capabilities to bolster its manufacturing efficiency and innovation.

  • Acquisition Value: ₹135 crore
  • Objective: Strengthening RPG Life Sciences' position in the API market
  • Impact: Expansion of product portfolio and manufacturing capabilities

Raghava Life Sciences, known for its robust API offerings, aligns with RPG Life Sciences' vision of growth and innovation. This acquisition is expected to generate new opportunities for both companies and enhance their competitive edge in the pharmaceutical industry.

RPG Life Sciences' leadership expressed optimism about this acquisition, highlighting its potential to drive long-term growth and deliver enhanced value to stakeholders.

For further updates on this acquisition and its implications for the pharmaceutical industry, stay tuned to our digital news portal.